Symptomatic AML or tumors measuring > 4–6 cm are widely accepted as indications for therapeutic treatments, including surgical resection, selective transarterial embolization, and mammalian target of rapamycin (mTOR) inhibitors [23]. Here, MTOR is linked to acute myeloid leukemia.